Healthcare-Acquired Infections: Devices, Pharmaceuticals, and Environmental Products
Report Highlights
The global market HCAI Control should grow from $24.0 billion in 2021 to $36.2 billion by 2026, at compound annual growth rate (CAGR) of 8.6% for the period of 2021-2026.
Report Includes
- 72 tables
- An updated review of the global healthcare-acquired infection (HCAI)-control market
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of select antimicrobials drugs and environment sterilization/disinfection products currently used or under development for treatment of healthcare-associated infections
- Market outlook and forecast trends of pharmaceutical treatment (antimicrobials and vaccines), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (catheters, patient ventilation devices, sterile intravenous [IV] filters) that prevent the occurrence of nosocomial infections
- Estimation of the market size and revenue forecasts for HCAI-control market, and corresponding market share analysis by key market segments — technology type, application, and geography
- Discussion of the key market dynamics, industry structure, regulatory approval, market deterrents, unmet needs and other factors driving opportunities in microbiology research
- A look at the pipeline products for antimicrobial resistance (AMR), hospital surveillance methods and tools used to control HCAI infections
- Review of the U.S. patent grants for innovations in infectious diseases control and viral infections
- Profile descriptions of the leading industry players including 3M, Merck, Novartis’, Pfizer, Roche, and Sanofi
Report Scope
The report focuses on select drugs (antimicrobials), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (e.g., catheters, patient ventilation devices, sterile IV filters) that prevent the occurrence of nosocomial infections.
Within each type of treatment, regional analyses will focus on the Americas (i.e., Canada, the U.S., Mexico, Central America and South America), EMRA (i.e., Europe, the Middle East, Russia and Africa) and Asia-Pacific (i.e., Japan, China, India, other Western Pacific countries such as Australia and New Zealand, and other Southeast Asian countries).
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for healthcare-acquired infection (HCAI) control should grow from $18.9 billion in 2018 to $24.7 billion by 2023 at a compound annual growth rate (CAGR) of 5.4% from 2018 through 2023.
Report Includes
- 42 data tables and 32 additional tables
- Industry analysis of the global healthcare-acquired infection (HCAI) control market
- Detailed overview and trend analysis of pharmaceutical treatment (antimicrobials and vaccines), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (catheters, patient ventilation devices, sterile intravenous [IV] filters) that prevent these infections
- Analyses of global market trends with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Emphasis on selected devices, pharmaceuticals and environmental products currently employed or under development for treatment of viral, bacterial and fungal infections
- Analysis of antimicrobial resistance and more specifically antibiotic resistance as a cause for these infections
- A look at the hospital surveillance methods and tools currently being used to prevent these infections
- Regional analysis of the market covering Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, Russia and Africa); and Asia-Pacific (i.e. Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries)
- Information on key patents and newer research developments in sterilization systems and devices
- Examination of vendor landscape and profiles of key players in the HCAI market, including Novartis, Pfizer, Roche, 3M Healthcare and Sanofi Pasteur
Report Highlights
The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
Report Includes
- Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020
- Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
- Information needed to understand the current market and to address the emerging market.
Report Highlights
The global market for selected HAI treatments was nearly $12.1. billion in 2012. The market is expected to reach $14.0 billion in 2013 and nearly $20.8 billion in 2018 with a compound annual growth rate (CAGR) of 8.2%.
Report Includes
- Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
- Background on the structure of the HAI market and the opportunities available as well as the chief challenges it faces
- Information needed to understand the current market and to address the emerging market
- Comprehensive company profiles of key players in the market.
Report Highlights
The global market for healthcare-acquired infection treatments were nearly $16 billion in year 2010. This market is estimated to be around $18.3 billion in the year 2011 and is forecasted to reach $25.6 billion by 2016 at a CAGR of 7.0% for five year period.